Literature DB >> 21923680

Key points for designing and reporting Helicobacter pylori therapeutic trials: a personal view.

Xavier Calvet1, Javier P Gisbert, David Suarez.   

Abstract

BACKGROUND &
OBJECTIVES: The aim of this document is to provide a methodological framework and to review key aspects for adequately designing trials to evaluate new treatments for Helicobacter pylori infection.
METHODS: Non-systematic literature review. RESULTS &
CONCLUSIONS: Regarding the design of the article, we suggest selecting for future trials drugs to which H. pylori has no significant primary resistances and evaluating therapies with pilot studies before engaging in randomized trials. The manuscript defines how the number and type of H. pylori diagnostic tests necessary before and after the trial depend on the setting and reliability of the tests. It recommends the best methods and timing for H. pylori testing before and after therapy. Other recommendations are using current standard treatments as comparators of new therapies, determining antibiotic sensitivity - whenever useful and possible - using adequate randomization and allocation concealment but not necessarily blinding, and performing an intention-to-treat and a per-protocol analysis. In addition, we give basic tips for reporting and discussing study results.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21923680     DOI: 10.1111/j.1523-5378.2011.00890.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  3 in total

1.  Helicobacter pylori therapy demystified.

Authors:  David Y Graham; Maria P Dore
Journal:  Helicobacter       Date:  2011-10       Impact factor: 5.753

Review 2.  Non-pharmacological treatment of Helicobacter pylori.

Authors:  Haim Shmuely; Noam Domniz; Jacob Yahav
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

3.  Rescue Therapy for Helicobacter pylori Infection 2012.

Authors:  Javier P Gisbert
Journal:  Gastroenterol Res Pract       Date:  2012-02-28       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.